Skip to content

FDA approves vaccine treatment for prostate cancer

Earlier in the week, I wrote about a cancer vaccine treatment that Stanford pathologist Edgar Engleman, MD, developed in the early 90s. As expected, the FDA gave the vaccine, called Provenge, the thumbs up today; according to Dow Jones (subscription required), the agency approved Provenge for patients with advanced prostate cancer who have failed hormone therapy treatment.

Popular posts

Intermittent fasting: Fad or science-based diet?

Are the health-benefit claims from intermittent fasting backed up by scientific evidence? John Trepanowski, postdoctoral research fellow at the Stanford Prevention Research Center,weighs in.